24
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Embed Size (px)

Citation preview

Page 1: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 2: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

PD-1/ PD-L1 pathway in suppressing anti-tumor immunity

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 3: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Slide 3

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 4: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Nivolumab <br />(ONO4538/BMS936558)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 5: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Study design: Investigator initiated, 2 cohorts Phase II

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 6: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Key inclusion criteria

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 7: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Study schedule

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 8: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Demographics

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 9: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Adverse events: Regardless of causality <br /> (>=4 patients)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 10: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Slide 10

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 11: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Serious adverse events<br />(Treatment-related)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 12: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Clinical Effect : Best Overall Response

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 13: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

A Responder with Serous adenoca : <br />Nivolumab 3mg/kg

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 14: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

A Responder with Clear cell carcinoma :<br />Nivolumab 3mg/kg

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 15: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Best overall responses in all patients

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 16: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Best overall responses in all patients in 2 cohorts

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 17: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Summary

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 18: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Conclusions

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 19: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Acknowledgements

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 20: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Research group

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 21: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Slide 21

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 22: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Clinical Effect : Response Duration

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 23: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Best overall responses in all patients

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Page 24: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

Slide 24

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting